Drug Profile
Panagen
Alternative Names: Double-stranded human DNA - Panagen; Fragmented DNA - Panagen; Placental DNA - Panagen; Sodium deoxyribonucleate - PanagenLatest Information Update: 26 Jul 2016
Price :
$50
*
At a glance
- Originator Panagen LLC
- Class DNA; Oligonucleotides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 26 Jul 2016 No recent reports on development identified - Phase-II for Breast cancer (Combination therapy) in Russia (PO)
- 01 May 2012 Panagen completes a phase II trial in Breast cancer (combination therapy) in Russia (NCT02115984)
- 01 May 2010 Phase-II clinical trials in Breast cancer (combination therapy) in Russia (PO)